Literature DB >> 19438745

Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.

Philip V Kaye1, Syeda A Haider, Mohammed Ilyas, Peter D James, Irshad Soomro, Wasek Faisal, James Catton, Simon L Parsons, Krish Ragunath.   

Abstract

AIMS: The Vienna classification is used to classify dysplasia in Barrett's oesophagus (BO), but reproducibility and value of diagnosis of lower grades in particular are often questioned. The aim was to test the diagnostic variability and correlation with patient outcome and to attempt to define histological features causing discrepant diagnoses, as well as to test the impact of adding p53 immunohistochemistry on reproducibility and prediction of outcome. METHODS AND
RESULTS: One hundred and forty-three patients with 154 sets of biopsy specimens originally diagnosed with Barrett's dysplasia were retrieved from the pathology records of Nottingham University Hospital. Thirty-two Barrett's patients without dysplasia were added. Anonymized slides were graded independently by five pathologists without and with p53-stained slides. Interobserver variation, correlation with outcome and diagnostic accuracy were determined. Weighted kappa scores between pairs of pathologists showed substantial agreement and improved after p53 immunohistochemistry. Agreement with the original diagnosis was substantially lower. Fourteen of 34 low-grade dysplasias (LGD) and 27 of 30 high-grade dysplasias on consensus progressed within 10 years compared with 18/94 and 28/39 of original diagnoses. Progression correlated with p53 positivity.
CONCLUSION: The Vienna classification is useful and reproducible in BO. Consensus diagnosis by gastrointestinal pathologists produces high specificity and predictive value, even for LGD. p53 immunohistochemistry assists in diagnosis in difficult cases and predicts progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438745     DOI: 10.1111/j.1365-2559.2009.03288.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  36 in total

Review 1.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

2.  The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Authors:  B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

3.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 4.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 5.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

6.  Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus.

Authors:  Meghan Jankowski; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 7.  Low grade dysplasia in Barrett's esophagus: Should we worry?

Authors:  Vamshi P Jagadesham; Clive J Kelty
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

Review 8.  Barrett's esophagus in 2016: From pathophysiology to treatment.

Authors:  Irene Martinucci; Nicola de Bortoli; Salvatore Russo; Lorenzo Bertani; Manuele Furnari; Anna Mokrowiecka; Ewa Malecka-Panas; Vincenzo Savarino; Edoardo Savarino; Santino Marchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

9.  Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles.

Authors:  Heewon A Kwak; Xiuli Liu; Daniela S Allende; Rish K Pai; John Hart; Shu-Yuan Xiao
Journal:  Mod Pathol       Date:  2016-05-20       Impact factor: 7.842

10.  SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.

Authors:  Sophie van Olphen; Katharina Biermann; Manon C W Spaander; Florine Kastelein; Ewout W Steyerberg; Hans A Stoop; Marco J Bruno; Leendert H J Looijenga
Journal:  Am J Gastroenterol       Date:  2015-09-01       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.